bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary figure S4 from Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner
Authors: Esfandiari Arman , Hawthorne Thomas A. , Nakjang Sirintra , Lunec John
Published: April 2023

Supplementary figure S4: A) Time-course of cell cycle distribution changes over 72 hours of treatment using FACS analysis. NGP and SJSA-1 cells were treated either with DMSO solvent control (Black), 2.5ÂµM GSK2830371 (Blue), (GI50) Nutlin-3 (Red) or Nutlin-3 + GSK2830371 combination (Purple). HCT116+/+ cells were treated with 0.5 Ã— Nutlin-3 GI50 in single and in combination treatment. B) Representative cell cycle distribution histograms for NGP and SJSA-1 cells indicating the increase in the proportion of Sub-G1events in response to 72 hours of treatment with GSK2830371 (WIP1i), Nutlin-3 and their combination.
Supplemental Data from Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC
Authors: Swick Adam D. , Prabakaran Prashanth J. , Miller Margot C. , Javaid Amal M. , Fisher Michael M. , Sampene Emmanuel , Ong Irene M. , Hu Rong , Iida Mari , Nickel Kwangok P. , Bruce Justine Y. , Wheeler Deric L. , Kimple Randall J.
Published: April 2023

Supplemental Data
Supplementary File 1 from Novel Indole-based Tambjamine-Analogues Induce Apoptotic Lung Cancer Cell Death through p38 Mitogen-Activated Protein Kinase Activation
Authors: Manuel-Manresa Pilar , Korrodi-Gregório Luís , Hernando Elsa , Villanueva Alberto , Martínez-García David , Rodilla Ananda M. , Ramos Ricard , Fardilha Margarida , Moya Juan , Quesada Roberto , Soto-Cerrato Vanessa , Pérez-Tomás Ricardo
Published: April 2023

QIAGEN Cancer Drug Targets Array file containing the raw data (Ct information) for the qPCR of all the conditions (both A549 and SW900 cell lines).
Supplementary figure S2 from Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner
Authors: Esfandiari Arman , Hawthorne Thomas A. , Nakjang Sirintra , Lunec John
Published: April 2023

Supplementary figure S2: A) Western blot shows optimisation of anti-WIP1 antibody (F-10) using siRNA mediated knockdown in MCF-7 cells. Following 24 and 48 hours of siRNA mediated knockdown conditions, MCF-7 cells were treated with 10Gy IR, lysates were collected after 4 hours and analysed by western blotting. All the bands shown were knocked down in response to four different WIP1 targeting siRNA constructs (WIP1.1-4) compared to the universal control siRNA (Cont. siRNA). WIP1 knockdown also resulted in higher and persistent pp53Ser15 most notably in response to the WIP1.2 siRNA construct. WIP1.1 Sense: GUGCCAUAGUAAUCUGCAU; WIP1.2 Sense: GGUGUAGUCAUACCCUCAA; WIP1.3 Sense: GCCCUUCCUAUAAUAGUCA; WIP1.4 Sense: UUGGCCUUGUGCCUACUAA Universal control Sense: GCGCGCUUUGUAGGAUUCG. B) Nutlin-3 and RG7388 SRB growth inhibition curves in MCF-7 cells in the presence and absence of 2.5ÂµM GSK2830371. C) On the left side two independent repeats of the western blot in Figure 2A showing degradation of WIP1 protein in MCF-7 cells over time following treatment with 2.5ÂµM GSK2830371. Full-length WIP1 band optical density (OD) was normalised to actin OD over time.
Supplementary Table S1 from Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner
Authors: Esfandiari Arman , Hawthorne Thomas A. , Nakjang Sirintra , Lunec John
Published: April 2023

Supplementary Table S1: A & B) List of genes with significantly increased mRNA levels in NGP cells 4 hours following treatment with 75nm RG7388 (GI50 in NGP cells) + 2.5ÂµM GSK2830371. Genes were ordered based on p-value following Benjamini-Hotchberg correction for multiple testing. OR: Odds ratio.
Supplementary Figure S5 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Authors: Beck Tim N. , Georgopoulos Rachel , Shagisultanova Elena I. , Sarcu David , Handorf Elizabeth A. , Dubyk Cara , Lango Miriam N. , Ridge John A. , Astsaturov Igor , Serebriiskii Ilya G. , Burtness Barbara A. , Mehra Ranee , Golemis Erica A.
Published: April 2023

(A and B) KM survival curves specimens with (A) high EGFR stratified by wild type (WT) or amplified (AMP) CCND1, or cases with (B) low EGFR stratified by p16 mRNA expression (TCGA cohort), (C) correlation between medium CDK6 (M) or high CDK6 (H) mRNA expression and CCND1 expression. m = slope. mRNA data for 243 HPV- HNSCC samples (6) were downloaded using cBioportal (26, 27). Please also see Figure 4.
Supplementary Figure S4 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Authors: Beck Tim N. , Georgopoulos Rachel , Shagisultanova Elena I. , Sarcu David , Handorf Elizabeth A. , Dubyk Cara , Lango Miriam N. , Ridge John A. , Astsaturov Igor , Serebriiskii Ilya G. , Burtness Barbara A. , Mehra Ranee , Golemis Erica A.
Published: April 2023

(A) Kaplan-Meier survival curves stratified by the expression of the indicated marker (patients treated with surgery only and patients treated with surgery and radiation therapy were included) and multivariate analysis for each marker. Kaplan-Meier survival curves for T1/2 and T3/4 tumors stratified by the expression of (B) NSDHL, (C) PTEN, and (D) BCAR1. Based on AQUA-expression scores.
Supplementary Figure S3 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Authors: Beck Tim N. , Georgopoulos Rachel , Shagisultanova Elena I. , Sarcu David , Handorf Elizabeth A. , Dubyk Cara , Lango Miriam N. , Ridge John A. , Astsaturov Igor , Serebriiskii Ilya G. , Burtness Barbara A. , Mehra Ranee , Golemis Erica A.
Published: April 2023

Kaplan-Meier survival curves for T1/2 and T3/4 tumors stratified by the expression of (A) EGFR and (B) HER2. Based on AQUA-expression scores.
Supplementary Figure S2 from Tumor-Suppressor Role of Notch3 in Medullary Thyroid Carcinoma Revealed by Genetic and Pharmacological Induction
Authors: Jaskula-Sztul Renata , Eide Jacob , Tesfazghi Sara , Dammalapati Ajitha , Harrison April D. , Yu Xiao-Min , Scheinebeck Casi , Winston-McPherson Gabrielle , Kupcho Kevin R. , Robers Matthew B. , Hundal Amrit K. , Tang Weiping , Chen Herbert
Published: April 2023

AB3 induces full-length of Notch3 and NICD3 to the similar level
Supplementary Figure S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Authors: Beck Tim N. , Georgopoulos Rachel , Shagisultanova Elena I. , Sarcu David , Handorf Elizabeth A. , Dubyk Cara , Lango Miriam N. , Ridge John A. , Astsaturov Igor , Serebriiskii Ilya G. , Burtness Barbara A. , Mehra Ranee , Golemis Erica A.
Published: April 2023

(A) Western blots for the indicated protein markers after siRNA depletion, (B) representative high and low staining immunofluorescent microscopy images for each marker. CK = cytokeratin (epithelial tumor stain), DNA = DAPI stain, C = control siRNA (siGL2), IB = immunoblotting, scale bar = 100μm.
Supplementary Figure S1 from Tumor-Suppressor Role of Notch3 in Medullary Thyroid Carcinoma Revealed by Genetic and Pharmacological Induction
Authors: Jaskula-Sztul Renata , Eide Jacob , Tesfazghi Sara , Dammalapati Ajitha , Harrison April D. , Yu Xiao-Min , Scheinebeck Casi , Winston-McPherson Gabrielle , Kupcho Kevin R. , Robers Matthew B. , Hundal Amrit K. , Tang Weiping , Chen Herbert
Published: April 2023

Notch3 is able to autoregulate its own expression
Supplementary Figure Legends from Tumor-Suppressor Role of Notch3 in Medullary Thyroid Carcinoma Revealed by Genetic and Pharmacological Induction
Authors: Jaskula-Sztul Renata , Eide Jacob , Tesfazghi Sara , Dammalapati Ajitha , Harrison April D. , Yu Xiao-Min , Scheinebeck Casi , Winston-McPherson Gabrielle , Kupcho Kevin R. , Robers Matthew B. , Hundal Amrit K. , Tang Weiping , Chen Herbert
Published: April 2023

Legends for supplementary figures
Supplementary Figures 1-4 and Supplementary Table 1-4 from T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin
Authors: Dziegielewska Barbara , Casarez Eli V. , Yang Wesley Z. , Gray Lloyd S. , Dziegielewski Jaroslaw , Slack-Davis Jill K.
Published: April 2023

Supplementary Figure 1: Relative T-type Ca2+ channel gene expression; Supplementary Figure 2: Down regulation of T-type Ca2+ channel gene expression decreases survivin protein level; Supplementary Figure 3: Effects of Mibefradil on AKT activity and its role in survivin stabilization; Supplementary Figure 4: Effects of carboplatin and down regulation of T-type Ca2+ channel expression on survivin expression; Supplementary Table 1: Sequence of siRNA targeted against T-type channel subunit; Supplementary Table 2: Sequence of primers designed for RT-qPCR amplification for gene expression; Supplementary Table 3: Sequence of primers designed for amplification of genomic DNA at the BIRC5 promoter containing and in close proximity to FoxO binding sequence (BS, Fig 3D); Supplementary Table 4: Combination indexes calculated for sequential treatment with the indicated concentrations of Mibefradil and carboPt in selected ovarian cancer cell lines (Fig 4A).
Supplemental table S1 from The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors
Authors: Zhang Hui , Patel Atish , Wang Yi-Jun , Zhang Yun-Kai , Kathawala Rishil J. , Qiu Long-Hui , Patel Bhargav A. , Huang Li-Hua , Shukla Suneet , Yang Dong-Hua , Ambudkar Suresh V. , Fu Li-Wu , Chen Zhe-Sheng
Published: April 2023

Ibrutinib significantly sensitizes ABCB1-overexpressing cells to vincristine and colchicine.
Supplementary Figure Legends from An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Authors: O'Neil Jennifer , Benita Yair , Feldman Igor , Chenard Melissa , Roberts Brian , Liu Yaping , Li Jing , Kral Astrid , Lejnine Serguei , Loboda Andrey , Arthur William , Cristescu Razvan , Haines Brian B. , Winter Christopher , Zhang Theresa , Bloecher Andrew , Shumway Stuart D.
Published: April 2023

Supplementary figure, table and data legend
Fig. S1 from The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors
Authors: Zhang Hui , Patel Atish , Wang Yi-Jun , Zhang Yun-Kai , Kathawala Rishil J. , Qiu Long-Hui , Patel Bhargav A. , Huang Li-Hua , Shukla Suneet , Yang Dong-Hua , Ambudkar Suresh V. , Fu Li-Wu , Chen Zhe-Sheng
Published: April 2023

Cytotoxicity assays of ibrutinib alone in the drug-resistant and parental cells.
Supplementary Data-Single Agent Response from An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Authors: O'Neil Jennifer , Benita Yair , Feldman Igor , Chenard Melissa , Roberts Brian , Liu Yaping , Li Jing , Kral Astrid , Lejnine Serguei , Loboda Andrey , Arthur William , Cristescu Razvan , Haines Brian B. , Winter Christopher , Zhang Theresa , Bloecher Andrew , Shumway Stuart D.
Published: April 2023

raw single agent response data; response is represented as fractional viability
Supplementary Information from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
Authors: Martinez-Font Esther , Felipe-Abrio Irene , Calabuig-Fariñas Silvia , Ramos Rafael , Terrasa Josefa , Vögler Oliver , Alemany Regina , Martín-Broto Javier , Obrador-Hevia Antònia
Published: April 2023

Supplementary Table 1. Cell lines characteristics; Supplementary Table 2. Expression of ÃŽÂ²-catenin in STS cell lines; Supplementary Table 3. Variables used in the correlation analysis; Supplementary Table 4. Correlation analysis based on Spearman's Rho
Supplementary Figure S3 from Human Leukocyte Antigen–Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer
Authors: Patterson Andrea M. , Kaabinejadian Saghar , McMurtrey Curtis P. , Bardet Wilfried , Jackson Ken W. , Zuna Rosemary E. , Husain Sanam , Adams Gregory P. , MacDonald Glen , Dillon Rachelle L. , Ames Harold , Buchli Rico , Hawkins Oriana E. , Weidanz Jon A. , Hildebrand William H.
Published: April 2023

HLA-A*02:01-negative tissues as determined by HLA-typing do not stain with BB7.2 or RL21A.
Supplementary Figure 3 from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
Authors: Martinez-Font Esther , Felipe-Abrio Irene , Calabuig-Fariñas Silvia , Ramos Rafael , Terrasa Josefa , Vögler Oliver , Alemany Regina , Martín-Broto Javier , Obrador-Hevia Antònia
Published: April 2023

Supplementary Figure 3. Expression of Wnt/ÃŽÂ²-catenin target genes in response to Wnt inhibitors
Supplementary Tables 1 - 2 from Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties
Authors: Seifert Oliver , Plappert Aline , Fellermeier Sina , Siegemund Martin , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

PDF file - 85K, Supplementary Table 1: In vitro cytotoxicity; Supplementary Table 2: Pharmacokinetic properties of EHD2 fusion proteins
Supplementary Figure S4 from Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Authors: Willuda Jörg , Linden Lars , Lerchen Hans-Georg , Kopitz Charlotte , Stelte-Ludwig Beatrix , Pena Carol , Lange Claudia , Golfier Sven , Kneip Christoph , Carrigan Patricia E. , Mclean Kirk , Schuhmacher Joachim , von Ahsen Oliver , Müller Jörg , Dittmer Frank , Beier Rudolf , El Sheikh Sherif , Tebbe Jan , Leder Gabriele , Apeler Heiner , Jautelat Rolf , Ziegelbauer Karl , Kreft Bertolt
Published: April 2023

Internalization and cytotoxicity of C4.4A-Ab.
Supplementary Figure Legend from Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties
Authors: Seifert Oliver , Plappert Aline , Fellermeier Sina , Siegemund Martin , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

PDF file - 41K
Supplementary Figure 3 from Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties
Authors: Seifert Oliver , Plappert Aline , Fellermeier Sina , Siegemund Martin , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

PDF file - 110K, Supplementary Figure 3. In vitro cytotoxicity of scFv-EHD2-scTRAIL in comparison with Db-scTRAIL.
Supplementary Figure S2 from Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Authors: Willuda Jörg , Linden Lars , Lerchen Hans-Georg , Kopitz Charlotte , Stelte-Ludwig Beatrix , Pena Carol , Lange Claudia , Golfier Sven , Kneip Christoph , Carrigan Patricia E. , Mclean Kirk , Schuhmacher Joachim , von Ahsen Oliver , Müller Jörg , Dittmer Frank , Beier Rudolf , El Sheikh Sherif , Tebbe Jan , Leder Gabriele , Apeler Heiner , Jautelat Rolf , Ziegelbauer Karl , Kreft Bertolt
Published: April 2023

C4.4A-Ab BAY 1112623 binds domain 1 of C4.4A.
Supplementary Figure 1 from Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties
Authors: Seifert Oliver , Plappert Aline , Fellermeier Sina , Siegemund Martin , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

PDF file - 132K, Supplementary Figure 1. Determination of melting points of the different fusion proteins by dynamic light scattering.
Supplementary Data from Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Authors: Willuda Jörg , Linden Lars , Lerchen Hans-Georg , Kopitz Charlotte , Stelte-Ludwig Beatrix , Pena Carol , Lange Claudia , Golfier Sven , Kneip Christoph , Carrigan Patricia E. , Mclean Kirk , Schuhmacher Joachim , von Ahsen Oliver , Müller Jörg , Dittmer Frank , Beier Rudolf , El Sheikh Sherif , Tebbe Jan , Leder Gabriele , Apeler Heiner , Jautelat Rolf , Ziegelbauer Karl , Kreft Bertolt
Published: April 2023

Supplementary Information (Supplementary Methods, Supplementary Tables, Supplementary Figure Legends, and References for Supplementary Information).
Supplementary Figure 1 and Supplementary Tables 1 through 3 from Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing
Authors: Estrella Jeannelyn S. , Tetzlaff Michael T. , Bassett Roland L. , Patel Keyur P. , Williams Michelle D. , Curry Jonathan L. , Rashid Asif , Hamilton Stanley R. , Broaddus Russell R.
Published: April 2023

Figure S1: Nonspecific VE1 immunohistochemical staining in normal tissue Table S1: VE1 immunohistochemistry results in colorectal carcinoma using the Bond method according to BRAF mutation status by sequence analysis Table S2: VE1 immunohistochemistry results in colorectal carcinoma using the Ventana method according to BRAF mutation status by sequence analysis Table S3: Additional molecular analyses of colorectal carcinoma with BRAF wild-type by sequencing and moderate to strong cytoplasmic staining in {greater than or equal to}20% by VE1 immunohistochemistry using the Bond method
Supplementary Data from Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Authors: Kuo Hsu-Ping , Ezell Scott A. , Schweighofer Karl J. , Cheung Leo W.K. , Hsieh Sidney , Apatira Mutiah , Sirisawad Mint , Eckert Karl , Hsu Ssucheng J. , Chen Chun-Te , Beaupre Darrin M. , Versele Matthias , Chang Betty Y.
Published: April 2023

Supplemental Figure Caption and Supplemental Tabes
Supplemental Figure 1 from Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Authors: Kuo Hsu-Ping , Ezell Scott A. , Schweighofer Karl J. , Cheung Leo W.K. , Hsieh Sidney , Apatira Mutiah , Sirisawad Mint , Eckert Karl , Hsu Ssucheng J. , Chen Chun-Te , Beaupre Darrin M. , Versele Matthias , Chang Betty Y.
Published: April 2023

Supplemental Figure 1
Supplemental Figures 1-9 from Vitamin D Enhances the Efficacy of Irinotecan through miR-627–Mediated Inhibition of Intratumoral Drug Metabolism
Authors: Sun Meiyan , Zhang Qunshu , Yang Xiaoyu , Qian Steven Y. , Guo Bin
Published: April 2023

Supplemental Figures 1-9 with Figure Legends
Supplementary Figure 3 from Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma
Authors: Seystahl Katharina , Papachristodoulou Alexandros , Burghardt Isabel , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick , Weller Michael
Published: April 2023

Expression of TGF-β-1,2,3 in human and murine glioma cell lines
Supplementary Figure 2 from Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma
Authors: Seystahl Katharina , Papachristodoulou Alexandros , Burghardt Isabel , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick , Weller Michael
Published: April 2023

TGF-β3 expression and patient survival, stratified for Verhaak subtypes - an analysis of the TCGA database
Supplementary Table 3 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Authors: Ang Joo Ern , Pandher Rupinder , Ang Joo Chew , Asad Yasmin J. , Henley Alan T. , Valenti Melanie , Box Gary , de Haven Brandon Alexis , Baird Richard D. , Friedman Lori , Derynck Mika , Vanhaesebroeck Bart , Eccles Suzanne A. , Kaye Stan B. , Workman Paul , de Bono Johann S. , Raynaud Florence I.
Published: April 2023

Characteristics of dose-dependent changes in candidate plasma metabolite pharmacodynamic biomarker concentrations in 41 patients, as determined on day 1 of pictilisib clinical trial. Cells with p-values <0.05 are shaded dark grey and those with p-values <0.10 and {greater than or equal to}0.05 are shaded light grey.
Supplementary Table 2 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Authors: Ang Joo Ern , Pandher Rupinder , Ang Joo Chew , Asad Yasmin J. , Henley Alan T. , Valenti Melanie , Box Gary , de Haven Brandon Alexis , Baird Richard D. , Friedman Lori , Derynck Mika , Vanhaesebroeck Bart , Eccles Suzanne A. , Kaye Stan B. , Workman Paul , de Bono Johann S. , Raynaud Florence I.
Published: April 2023

Summary of baseline reproducibility of candidate plasma metabolite biomarkers (n=17 patients).
Supplementary Table 1 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Authors: Ang Joo Ern , Pandher Rupinder , Ang Joo Chew , Asad Yasmin J. , Henley Alan T. , Valenti Melanie , Box Gary , de Haven Brandon Alexis , Baird Richard D. , Friedman Lori , Derynck Mika , Vanhaesebroeck Bart , Eccles Suzanne A. , Kaye Stan B. , Workman Paul , de Bono Johann S. , Raynaud Florence I.
Published: April 2023

Metabolite changes that constitute the Venn diagram in Figure 2. Significant changes listed are reductions (labelled "-1") or increases (labelled "1") in concentrations relative to the relevant controls.
Supplementary Figure 4 from FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer
Authors: McLaughlin Kylie A. , Nemeth Zsuzsanna , Bradley Conor A. , Humphreys Luke , Stasik Izabela , Fenning Catherine , Majkut Joanna , Higgins Catherine , Crawford Nyree , Holohan Caitriona , Johnston Patrick G. , Harrison Timothy , Hanna Gerard G. , Butterworth Karl T. , Prise Kevin M. , Longley Daniel B.
Published: April 2023

Combination of SAHA with IR in H460 and A549 cells using different treatment schedules
Supplementary Figures legend from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Authors: Murone Maximilien , Vaslin Chessex Anne , Attinger Antoine , Ramachandra Raghuveer , Shetty Shankar J. , Daginakatte Girish , Sengupta Saumitra , Marappan Sivapriya , Dhodheri Samiulla , Rigotti Stefania , Bachhav Yogeshwar , Brienza Silvano , Traxler Peter , Lang Marc , Aguet Michel , Zoete Vincent , Michielin Olivier , Nicholas Courtney , Johnson Faye M. , Ramachandra Murali , McAllister Andres
Published: April 2023

Legend for Supplementary Figures:1A,1B,1C,1D 2A,2B,2C;3A,3B
Supplementary Figure 3 from FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer
Authors: McLaughlin Kylie A. , Nemeth Zsuzsanna , Bradley Conor A. , Humphreys Luke , Stasik Izabela , Fenning Catherine , Majkut Joanna , Higgins Catherine , Crawford Nyree , Holohan Caitriona , Johnston Patrick G. , Harrison Timothy , Hanna Gerard G. , Butterworth Karl T. , Prise Kevin M. , Longley Daniel B.
Published: April 2023

IR-induced changes in cell surface expression of death receptors
Supplementary Figure 1 from FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer
Authors: McLaughlin Kylie A. , Nemeth Zsuzsanna , Bradley Conor A. , Humphreys Luke , Stasik Izabela , Fenning Catherine , Majkut Joanna , Higgins Catherine , Crawford Nyree , Holohan Caitriona , Johnston Patrick G. , Harrison Timothy , Hanna Gerard G. , Butterworth Karl T. , Prise Kevin M. , Longley Daniel B.
Published: April 2023

Response of H460 and A549 cells to IR
Supplementary Table S2 from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
Authors: Gordon Michael A. , D'Amato Nicholas C. , Gu Haihua , Babbs Beatrice , Wulfkuhle Julia , Petricoin Emanuel F. , Gallagher Isela , Dong Ting , Torkko Kathleen , Liu Bolin , Elias Anthony , Richer Jennifer K.
Published: April 2023

RPPA all significant proteins
Supplemental Methods and Figure Legends from Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors
Authors: Goglia Alexander G. , Delsite Robert , Luz Antonio N. , Shahbazian David , Salem Ahmed F. , Sundaram Ranjini K. , Chiaravalli Jeanne , Hendrikx Petrus J. , Wilshire Jennifer A. , Jasin Maria , Kluger Harriet M. , Glickman J. Fraser , Powell Simon N. , Bindra Ranjit S.
Published: April 2023

Contains Legends for Figures and additional methods
Supplementary Table 1 from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
Authors: Gordon Michael A. , D'Amato Nicholas C. , Gu Haihua , Babbs Beatrice , Wulfkuhle Julia , Petricoin Emanuel F. , Gallagher Isela , Dong Ting , Torkko Kathleen , Liu Bolin , Elias Anthony , Richer Jennifer K.
Published: April 2023

Cell line mutation status and culture conditions
Supplemental Figure 8 from Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors
Authors: Goglia Alexander G. , Delsite Robert , Luz Antonio N. , Shahbazian David , Salem Ahmed F. , Sundaram Ranjini K. , Chiaravalli Jeanne , Hendrikx Petrus J. , Wilshire Jennifer A. , Jasin Maria , Kluger Harriet M. , Glickman J. Fraser , Powell Simon N. , Bindra Ranjit S.
Published: April 2023

Additional data for hits from the primary screen
Supplementary Figure S2 from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
Authors: Gordon Michael A. , D'Amato Nicholas C. , Gu Haihua , Babbs Beatrice , Wulfkuhle Julia , Petricoin Emanuel F. , Gallagher Isela , Dong Ting , Torkko Kathleen , Liu Bolin , Elias Anthony , Richer Jennifer K.
Published: April 2023

SKBR3 western blot
Supplementary Figure S1 from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
Authors: Gordon Michael A. , D'Amato Nicholas C. , Gu Haihua , Babbs Beatrice , Wulfkuhle Julia , Petricoin Emanuel F. , Gallagher Isela , Dong Ting , Torkko Kathleen , Liu Bolin , Elias Anthony , Richer Jennifer K.
Published: April 2023

In vivo randomization/matching data
Supplemental Figure 2 from Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors
Authors: Goglia Alexander G. , Delsite Robert , Luz Antonio N. , Shahbazian David , Salem Ahmed F. , Sundaram Ranjini K. , Chiaravalli Jeanne , Hendrikx Petrus J. , Wilshire Jennifer A. , Jasin Maria , Kluger Harriet M. , Glickman J. Fraser , Powell Simon N. , Bindra Ranjit S.
Published: April 2023

HR and mNHEJ results of the high-throughput screen presented as a 2D RADaR plot.
Supplementary Figures S1-S13; Supplementary Tables S1-S3, Supplementary Materials and Methods and Supplementary References from Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress
Authors: Wang Chun Yan , Guo Su Tang , Wang Jia Yu , Liu Fen , Zhang Yuan Yuan , Yari Hamed , Yan Xu Guang , Jin Lei , Zhang Xu Dong , Jiang Chen Chen
Published: April 2023

Supplementary Figure S1. AUY922 does not significantly affect viability of normal colon epithelial cells; Supplementary Figure S2. Sensitivity of colon cancer cells to AUY922 is not associated with the expression levels of HSP90; Supplementary Figure S3. The general caspase inhibitor z-VAD-fmk efficiently inhibits AUY922-mediated inhibition of mutant KRAS colon cancer cell survival; Supplementary Figure S4. AUY922 kills colon cancer cells by induction of apoptosis; Supplementary Figure S5. AUY922 triggers reduction in the mitochondrial membrane potential, release of mitochondrial apoptogenic proteins in sensitive but not resistant colon cells; Supplementary Figure S6. Inhibition of Bim does not alter sensitivity of Caco-2 cells to AUY922; Supplementary Figure S7. Knockdown of PUMA or p53 does not inhibit cell death induced by AUY922; Supplementary Figure S8. Upregulation of Bim by AUY922 in mutant KRAS colon cancer cells is due to a transcriptional increase; Supplementary Figure S9. Knockdown of CHOP inhibits cell death induced by AUY922; Supplementary Figure S10. BGP-15 and 4-PBA attenuate XBP-1 splicing induced by AUY922; Supplementary Figure S11. Overexpression of GRP78 reduces AUY922-induced upregulation of CHOP and Bim; Supplementary Figure S12. A schematic model comparing different responses of mutant and wild-type KRAS colon cancer cells to AUY922; Supplementary Figure S13. AUY922 does not cause any significant change in the expression of STK33 in mutant KRAS colon cancer cells; Supplementary Table 1. List of Antibodies; Supplementary Table 2. List of reagents; Supplementary Table 3. siRNAs
Supplementary Tables S1-S7; Supplementary Figures S1-S2; and Supplementary Materials & Methods from Optimization of RGD-Containing Cyclic Peptides against αvβ3 Integrin
Authors: Wang Yan , Xiao Wenwu , Zhang Yonghong , Meza Leah , Tseng Harry , Takada Yoshikazu , Ames James B. , Lam Kit S.
Published: April 2023

General methods for library synthesis Table S1. MS and purity for cyclic peptide 1 derivatives Synthesis of focused libraries Table S2. Amino acids used in the synthesis of focused Library 1 and 2 Table S3. Amino acids used in the synthesis of focused Library 1. Table S4. Amino acids used in the synthesis of focused Library 2 NMR study of peptide 1 and 4 Experimental Constraints and Structure Calculation Table S5. Chemical shifts of peptide 1 at 295K, DMSO-d6. Table S6. Chemical shifts of peptide 4 at 295K, DMSO-d6. Table S7. Structure statistics for the ensembles of 15 calculated structures of peptide 1 and peptide 4 Figure S1. Representative regions of the 2D NOESY spectrum of 1 and 4. Figure S2. Superimposed solution structures are the ensembles of 15 structures for peptide 1 and 4. In vivo and ex vivo optical imaging Abbreviations Reference
Supplementary Figures 1 through 5 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells
Authors: Zeng Jun-Ying , Sharma Sharad , Zhou Yong-Qing , Yao Hang-Ping , Hu Xing , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

PDF - 424K, Supplementary Figure 1. Effect of BMS-777607 alone or in combination with AZD8055 on polyploidy and viability of Panc1 and BxPC3 cells; Supplementary Figure 2. Effect of siRNA-mediated knockdown of RON expression on BMS-777607-induced polyploidy; Supplementary Figure 3. Effect of BMS-777607 on DNA/chromosome content in L3.6pl cells and CSCs+24/44/ESA; Supplementary Figure 4. Effect of BMS-777607 alone or in combination with AZD8055 on apoptosis of L3.6pl cells; Supplementary Figure 5. Effect of BMS-777607 alone or plus AZD8055 on MCL1 and cyclin B expression in L3.6pl cells.
Supplementary Figure S6. NK-cells redistribute towards tumors and draining lymph nodes after treatment with trastuzumab-coding oncolytic virus from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
Authors: Liikanen Ilkka , Tähtinen Siri , Guse Kilian , Gutmann Theresia , Savola Paula , Oksanen Minna , Kanerva Anna , Hemminki Akseli
Published: April 2023

3-4 week-old male nude/NMRI mice (Taconic) bearing HER2-expressing N87 gastric cancer xenografts were treated in a mechanism of action experiment as in figure 4, but with adjusted doses: 3Ã-108 VP/tumor or saline on days 0, 4, 8, and 15, while one saline-treated group also received 5.0 Âµg/g of systemic commercial trastuzumab intraperitoneally (tras). On day 20, tumors, draining lymph nodes (DLNs) and spleens were collected, homogenized and analyzed by flow cytometry with CD49b NK-cell marker. Overall absolute levels of NK-cells did not differ between groups in any compartment. However, when distribution of NK cells into draining lymph nodes (left panel) and tumors (right panel) over the spleens of the animals was assessed, the oncolytic trastuzumab-coding virus (OV-tras) showed the highest ratio of NK cells in both target tissues; In particular, NK-cells showed homing towards the draining lymph nodes where they have been reported to e.g. mediate DC-editing and polarize activated CD4+ T-cells into T-helper 1 phenotype (36). Ratio of NK cells between compartments was calculated by dividing the average NK-cell frequency in tumors/lymph nodes by the average of NK-cells in spleens, each per 5Ã-104 cells. n=3 mice per group. Mock, animals treated with intratumoral saline injections; DLN, draining lymph node; OV-tras, oncolytic adenovirus coding for trastuzumab; OV, oncolytic control virus; tras, systemic trastuzumab therapy.
Supplementary Figure S3: Temporal expression of p-AKT after AD and edelfosine treatment in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Authors: Udayakumar Thirupandiyur S. , Stoyanova Radka , Shareef Mohammed M. , Mu Zhaomei , Philip Sakhi , Burnstein Kerry L. , Pollack Alan
Published: April 2023

(A) LNCaP cells {plus minus} AD were treated with edelfosine (10 µM) and the cells were harvested after 3, 6 and 18 h time points. Cell lysates were examined by Western blotting for p-AKT and total AKT. (B) ARv7 expression in 22RV1 cells. Cells were cultured in 10 cm tissue culture dishes in CM or AD medium and then treated edelfosine (10 µM). Treated cells were harvested after 24 h, whole-cell lysates were extracted, and ARv7 expression was determined by Western immunoblotting. The same blot was re-probed for β-actin.
Supplementary Figure Legends from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Authors: Udayakumar Thirupandiyur S. , Stoyanova Radka , Shareef Mohammed M. , Mu Zhaomei , Philip Sakhi , Burnstein Kerry L. , Pollack Alan
Published: April 2023

Supplementary Figure legends for Figures S1-S5.
Supplementary figures 1-6 from Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling
Authors: Nambiar Dhanya K. , Rajamani Paulraj , Deep Gagan , Jain Anil K. , Agarwal Rajesh , Singh Rana P.
Published: April 2023

Supplementary figure 1 shows the effect of silibinin and IR alone and in combination treatment for 48 h for the total cell number and number of colony formation in human prostate cancer 22RV1 cells. The combination treatment did not show any significant increase in the effect of IR for both the parameters. Supplementary figure 2 shows the representative histogram data for the analysis of cell cycle phase distribution. A prominent increase in G2/M phase peak can be noted in IR+silibinin combination treatment. Supplementary figure 3 shows that IR-induced expression of G2/M phase regulators are down-modulated in DU145 cells but not in HEK293 cells in the IR+silibinin combination treatment. This combination also decreased the expression of PCNA and survivin in DU145 and PC-3 cells. Supplementary figure 4 shows the measurement of ROS level which was higher in the IR+silibinin combination treatment and accompanied with down-modulation of antioxidant enzyme system in DU145 cells. Whereas as opposed to DU145 cells, ROS level was decreased in HEK-293 cells in the combination treatment which could provide protection to the cells. Supplementary figure 5 shows that IR induces nuclear translocation of EGFR in non-neoplastic JB6 cells which is not affected by the IR+silibinin combination treatment to the extent as observed in DU145 cells (figure 4). Supplementary figure 6 shows the parameters monitored for measuring the normal tissue toxicity in the tumor xenograft study in mice. The IR-induced adverse changes in the prostate and seminal vesicle, and decrease in neutrophil and monocytes counts were reversed in the combination treatment.
Primer sequences from Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling
Authors: Nambiar Dhanya K. , Rajamani Paulraj , Deep Gagan , Jain Anil K. , Agarwal Rajesh , Singh Rana P.
Published: April 2023

The table depicts the sequences of the gene primers used for the mRNA expression analysis.
Supplementary Table S1 from Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Authors: Singha Netai C. , Nekoroski Tara , Zhao Chunmei , Symons Rebecca , Jiang Ping , Frost Gregory I. , Huang Zhongdong , Shepard H. Michael
Published: April 2023

PEGPH20 increased NK-mediated ADCC.
Supplemental Figure 1 from Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Authors: Perera Timothy P.S. , Jovcheva Eleonora , Mevellec Laurence , Vialard Jorge , De Lange Desiree , Verhulst Tinne , Paulussen Caroline , Van De Ven Kelly , King Peter , Freyne Eddy , Rees David C. , Squires Matthew , Saxty Gordon , Page Martin , Murray Christopher W. , Gilissen Ron , Ward George , Thompson Neil T. , Newell David R. , Cheng Na , Xie Liang , Yang Jennifer , Platero Suso J. , Karkera Jayaprakash D. , Moy Christopher , Angibaud Patrick , Laquerre Sylvie , Lorenzi Matthew V.
Published: April 2023

A) Structure of JNJ-42541707, a structurally related compound to JNJ-42756493. B) 72h growth inhibition (IC50) of JNJ-42541707 against 236 cancer cell lines from multiple origins color coded based on FGFR1,2,4 mRNA overexpression and FGFR WT.
Supplementary Material Legends from Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Authors: Singha Netai C. , Nekoroski Tara , Zhao Chunmei , Symons Rebecca , Jiang Ping , Frost Gregory I. , Huang Zhongdong , Shepard H. Michael
Published: April 2023

Supplementary Material Legends
Supplementary Figure S5 from Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Authors: Singha Netai C. , Nekoroski Tara , Zhao Chunmei , Symons Rebecca , Jiang Ping , Frost Gregory I. , Huang Zhongdong , Shepard H. Michael
Published: April 2023

PEGPH20 depletes HA from HAhigh tumors and increases trastuzumab accessibility in HAhigh tumors.
Supplementary Movie 4 from Reversible Action of Diaminothiazoles in Cancer Cells Is Implicated by the Induction of a Fast Conformational Change of Tubulin and Suppression of Microtubule Dynamics
Authors: Thomas Nisha E. , Thamkachy Reshma , Sivakumar Krishnankutty C. , Sreedevi Krishnakumar J. , Louis Xavier Lieben , Thomas Sannu A. , Kumar Rohith , Rajasekharan Kallikat N. , Cassimeris Lynne , Sengupta Suparna
Published: April 2023

AVI - 1221KB, Supplemental Movie SM4: Molecular simulation of colchicine bound to tubulin at lower pH.
Supplementary Figure S4 from Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Authors: Singha Netai C. , Nekoroski Tara , Zhao Chunmei , Symons Rebecca , Jiang Ping , Frost Gregory I. , Huang Zhongdong , Shepard H. Michael
Published: April 2023

PEGPH20 treatment does not alter NK cell effector function or antibody binding to HER2 on HAhigh SKOV3/HAS2 cells in vitro.
Supplementary Movie 2 from Reversible Action of Diaminothiazoles in Cancer Cells Is Implicated by the Induction of a Fast Conformational Change of Tubulin and Suppression of Microtubule Dynamics
Authors: Thomas Nisha E. , Thamkachy Reshma , Sivakumar Krishnankutty C. , Sreedevi Krishnakumar J. , Louis Xavier Lieben , Thomas Sannu A. , Kumar Rohith , Rajasekharan Kallikat N. , Cassimeris Lynne , Sengupta Suparna
Published: April 2023

AVI - 1278KB, Supplemental Movie SM2: Molecular simulation of DAT1 bound to tubulin at lower pH.
Supplementary Figure S2 from Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Authors: Singha Netai C. , Nekoroski Tara , Zhao Chunmei , Symons Rebecca , Jiang Ping , Frost Gregory I. , Huang Zhongdong , Shepard H. Michael
Published: April 2023

HAS2 overexpression does not alter specific cell surface protein expression.
Supplementary Materials and Methods and Supplementary Figure Legends from Reversible Action of Diaminothiazoles in Cancer Cells Is Implicated by the Induction of a Fast Conformational Change of Tubulin and Suppression of Microtubule Dynamics
Authors: Thomas Nisha E. , Thamkachy Reshma , Sivakumar Krishnankutty C. , Sreedevi Krishnakumar J. , Louis Xavier Lieben , Thomas Sannu A. , Kumar Rohith , Rajasekharan Kallikat N. , Cassimeris Lynne , Sengupta Suparna
Published: April 2023

PDF - 74KB, Supplementary Materials and Methods and Figure Legends.
Supplemental Tables 1-3 and Supplemental Figure 1 from Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology
Authors: Husain Hatim , Nykin David , Bui Nam , Quan Daniel , Gomez German , Woodward Brian , Venkatapathy Sumathi , Duttagupta Radha , Fung Eric , Lippman Scott M. , Kurzrock Razelle
Published: April 2023

Supplemental Table 1 - Assayed Genes on the Oncoscan Assay Supplemental Table 2 - Total list of CNVs for Case 1 and Case 2 Supplemental Table 3 - List of CNVs Filtered by COSMIC Database for Cases 1-7 Supplemental Figure 1 - Quantitative PCR Validation of EGFR Identification
Supplementary Figure 3 from Reversible Action of Diaminothiazoles in Cancer Cells Is Implicated by the Induction of a Fast Conformational Change of Tubulin and Suppression of Microtubule Dynamics
Authors: Thomas Nisha E. , Thamkachy Reshma , Sivakumar Krishnankutty C. , Sreedevi Krishnakumar J. , Louis Xavier Lieben , Thomas Sannu A. , Kumar Rohith , Rajasekharan Kallikat N. , Cassimeris Lynne , Sengupta Suparna
Published: April 2023

PDF - 479KB, Supplemental Fig S3: Effect of pH on colchicine binding to tubulin.
Supplementary Material for Talbert and Yang et al. from Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities
Authors: Talbert Erin E. , Yang Jennifer , Mace Thomas A. , Farren Matthew R. , Farris Alton B. , Young Gregory S. , Elnaggar Omar , Che Zheng , Timmers Cynthia D. , Rajasekera Priyani , Maskarinec Jennifer M. , Bloomston Mark , Bekaii-Saab Tanios , Guttridge Denis C. , Lesinski Gregory B.
Published: April 2023

Supplementary Material contains Supplementary Figures 1-5 and Supplementary Table 1. Supplementary Figure 1. MEK162 treatment prevents cancer-induced weight loss and muscle wasting. Supplementary Figure 2. Development of a MEK162 resistant C-26 tumor cell line. Supplementary Figure 3. MEK162 prevents cancer-induced weight loss and muscle wasting in part via a tumor extrinsic mechanism. Supplementary Figure 4. MEK162 prevents cancer-induced weight loss and muscle wasting when used in combination with buparlisib. Supplementary Figure 5. MEK162 and buparlisib modulate the immune system. Supplementary Table 1. Primer sequences used for real-time RT-PCR.
Supplementary Figure 1 from Reversible Action of Diaminothiazoles in Cancer Cells Is Implicated by the Induction of a Fast Conformational Change of Tubulin and Suppression of Microtubule Dynamics
Authors: Thomas Nisha E. , Thamkachy Reshma , Sivakumar Krishnankutty C. , Sreedevi Krishnakumar J. , Louis Xavier Lieben , Thomas Sannu A. , Kumar Rohith , Rajasekharan Kallikat N. , Cassimeris Lynne , Sengupta Suparna
Published: April 2023

PDF - 4536KB, Supplemental Fig S1: Reversible action of DAT1 on mitotic block and cell morphology in HCT 116 cells.
Supplementary Table S2 from Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma
Authors: Ilmer Matthias , Garnier Agnès , Vykoukal Jody , Alt Eckhard , von Schweinitz Dietrich , Kappler Roland , Berger Michael
Published: April 2023

Phospho/total protein ratios as evaluated by RPPA screening (Fig. 1).
Figure Legend Ssupplemental Figure1 from Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo
Authors: Helfrich Barbara A. , Kim Jihye , Gao Dexiang , Chan Daniel C. , Zhang Zhiyong , Tan Aik-Choon , Bunn Paul A.
Published: April 2023

Figure legend Supplemental Figure 1
Supplementary Table 2 from A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer
Authors: LaBonte Melissa J. , Yang Dongyun , Zhang Wu , Wilson Peter M. , Nagarwala Yasir M. , Koch Kevin M. , Briner Colleen , Kaneko Tomomi , Rha Sun-Young , Gladkov Oleg , Urba Susan G. , Sakaeva Dina , Pishvaian Michael J. , Hsieh Ruey-Kuen , Lee Wei-Ping , Lenz Heinz-Josef
Published: April 2023

RECIST response by intatumoral median gene expression
Supplementary Figure Legends from A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer
Authors: LaBonte Melissa J. , Yang Dongyun , Zhang Wu , Wilson Peter M. , Nagarwala Yasir M. , Koch Kevin M. , Briner Colleen , Kaneko Tomomi , Rha Sun-Young , Gladkov Oleg , Urba Susan G. , Sakaeva Dina , Pishvaian Michael J. , Hsieh Ruey-Kuen , Lee Wei-Ping , Lenz Heinz-Josef
Published: April 2023

Figure Legends for Supplementary Figures
Supplementary Materials and Methods, Supplementary Tables 1 through 9, and Supplementary Figures 1 through 8 from Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia
Authors: Suryani Santi , Bracken Lauryn S. , Harvey Richard C. , Sia Keith C.S. , Carol Hernan , Chen I-Ming , Evans Kathryn , Dietrich Philipp A. , Roberts Kathryn G. , Kurmasheva Raushan T. , Billups Catherine A. , Mullighan Charles G. , Willman Cheryl L. , Loh Mignon L. , Hunger Stephen P. , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

Supplementary Materials and Methods. Supplementary Table S1. QC of Affymetrix U133_Plus_2.0 Data. Supplementary Table S2. Summary of the Objective Response Measure (ORM) scoring methodology. Supplementary Table S3. Correlation of xenograft with parent U133_Plus_2.0 expression. Supplementary Table S4. Probe sets where parent expression is always greater than xenograft. Supplementary Table S5. Probe sets where xenograft expression is always greater than parent. Supplementary Table S6. Complete summary of in vivo AZD1480 single agent responses for individual mice. Supplementary Table S7. In vitro Combination Indices (CIs) for AZD1480 and selumetinib. Supplementary Table S8. In vivo responses of JAK-mutated ALL xenografts to AZD1480/selumetinib combination treatment. Supplementary Table S9. Complete summary of in vivo AZD1480 single agent and AZD1480/selumetinib combination responses for individual mice. Supplementary Figure S1. Chemical structures of (A) AZD1480 and (B) selumetinib. Supplementary Figure S2. Relationship between high CRLF2 expression and engraftment potential of the P9906 cohort. Supplementary Figure S3. Probe set expression by range. Supplementary Figure S4. Heatmap of microarray gene expression data corresponding to the qRT-PCR data shown in Figure 1. Supplementary Figure S5. In vitro cytotoxicity of AZD1480 against ALL xenograft cells. Supplementary Figure S6. In vivo efficacy of single agent AZD1480 against ALL xenografts. Supplementary Figure S7. Time of drug exposure affects synergistic interactions of AZD1480 and selumetinib against JAK-mutated ALL xenografts. Supplementary Figure S8. The extent of inhibition of the JAK/STAT and MAPK signaling pathways depends on the length of exposure to AZD1480/selumetinib.
Supplementary Information: Supplementary Figures 1-5 from Targeted Drug Delivery with an Integrin-Binding Knottin–Fc–MMAF Conjugate Produced by Cell-Free Protein Synthesis
Authors: Currier Nicolas V. , Ackerman Shelley E. , Kintzing James R. , Chen Rishard , Filsinger Interrante Maria , Steiner Alexander , Sato Aaron K. , Cochran Jennifer R.
Published: April 2023

Supplementary Figure 1. Standard curves for quantification of cellular integrin expression; Supplementary Figure 2. Competition binding to U87MG tumor cell surface integrins; Supplementary Figure 3. Inhibition of tumor cell proliferation. U87MG, A2780 and MB-468 cells were incubated with varying concentrations of 2.5F-Fc-MMAF, and CTRL-Fc-MMAF;Supplementary Figure 4. Growth inhibition of subcutaneous U87MG tumors implanted into Nu/Nu mice; Supplementary Figure 5. Weight monitoring.
Supplemental Figure 5 from ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model
Authors: Mittapalli Rajendar K. , Chung Alexander H. , Parrish Karen E. , Crabtree Donna , Halvorson Kyle G. , Hu Guo , Elmquist William F. , Becher Oren J.
Published: April 2023

Brain distribution of Elacridar in ABC KO and ABC WT is not significantly different.
Supplemental Figure 4 from ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model
Authors: Mittapalli Rajendar K. , Chung Alexander H. , Parrish Karen E. , Crabtree Donna , Halvorson Kyle G. , Hu Guo , Elmquist William F. , Becher Oren J.
Published: April 2023

Representative images of four vehicle-treated murine brainstem gliomas in ABC KO and ABC WT mice (10X and 40X images).